ESC 365 - Beta-blockers for LQT3: Contraindicated, acceptable or the drug of choice?

EHRA Premium Access

Beta-blockers for LQT3: Contraindicated, acceptable or the drug of choice?

Session: Medical treatment of channelopathies: effective and safe?

Topic: Pharmacology

Speaker: Professor A. Wilde (Amsterdam, NL)

Event: EHRA EUROPACE - CARDIOSTIM 2017

Congress Presentation

Add to my library

About the speaker

Professor Arthur Wilde

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

13 presentations

5 followers

3 more presentations in this session

Quinidine for Brugada and what to do with Quinidine intolerance.

Speaker: Professor W. Shimizu (Tokyo, JP)

Ranolazine for LQT3: s treatment that found it's disease?

Speaker: Professor S. Viskin (Tel Aviv, IL)

LQT3 – the role of Ajmaline challenge and of Flecainide and mexilletine in treatment.

Speaker: Professor P. Schwartz (Cusano Milanino, IT)

Access the full session

Medical treatment of channelopathies: effective and safe?

Speakers: Professor A. Wilde, Professor W. Shimizu, Professor S. Viskin, Professor P. Schwartz

About the event

EHRA EUROPACE - CARDIOSTIM 2017

18 June - 21 June 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources